Kaplan Gilla's Form 4 filing
Tyra Biosciences, Inc. (TYRA) · filed Mar 27, 2026
- Accession no.
- 0001193125-26-129239
- Filed
- Mar 27, 2026
- Trade date
- Mar 25-26, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $528.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kaplan GillaCIK 0001247024 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | MOption exerciseAcquired | +14,295 | $2.25 | +$32,163.75 | 42,526 | Direct | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −14,295 | $36.97 | −$528,486.15 | 28,231 | Direct | |
| Mar 26, 2026 | Common Stock | MOption exerciseDisposed | −53,172 | $2.25 | −$119,637 | 81,403 | Direct | |
| Mar 26, 2026 | Common Stock | DReturned to the companyDisposed | −53,172 | $37.75 | −$2,007,243 | 28,231 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | MOption exerciseDisposed | −14,295 | $0.00 | $0 | 53,172 | Direct | |
| Mar 26, 2026 | Common Stock | MOption exerciseDisposed | −53,172 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.